News
Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...
Fifteen of the biotechnology company’s products delivered at least double-digit sales growth in the second quarter.
Non-GAAP earnings per share for Q2 2025 beat estimates by 14.0%, rising to $6.02 (non-GAAP) and up 21% year over year (non-GAAP). Revenue increased 9% to $9.2 billion, exceeding analyst expectations ...
Amgen narrowed its 2024 adjusted earnings estimate and now expects a profit of $19.10 to $20.10 per share, compared with its previous view of $19.00 to $20.20.
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed ...
Amgen AMGN, -0.76% said fourth-quarter net profit declined to $163 million, or 15 cents per share, from $210 million, or 19 cents per share, in the fourth quarter of 2000.
Amgen reported adjusted profit of $1.235 billion, down 2% from $1.265 billion a year prior, and earnings per share of $1.14 a share, up 2% from $1.12 a share a year prior.
Amgen said fourth-quarter profit rose 1 percent as research spending climbed faster than sales of its anemia and cancer drugs. Net income climbed to $833 million, or 71 cents a share, from $824 ...
Thousand Oaks biotech firm Amgen Inc. said its profit jumped 7% in the second quarter as sales of several key drugs increased. The results, released after markets closed Thursday, were better than ...
Analysts estimate that Amgen will report an earnings per share (EPS) of $5.26. The announcement from Amgen is eagerly anticipated, with investors seeking news of surpassing estimates and favorable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback